Pharmacological treatment of obesity

Sleep Loss and Obesity: Intersecting Epidemics

Volumn , Issue , 2012, Pages 203-225

  Kabra, Dhiraj G ^a   Kabra, Uma D ^a   Tschöp, Matthias H ^a   Hofmann, Susanna ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84955338194     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-3492-4_14     Document Type: Chapter

References (211)

1. Ogden CL, Carroll MD, Flegal KM. Prevention and management of the global epidemic of obesity: report of the WHO consultation on obesity 1997, 3-5 June; Geneva, Switzerland.
2. Ogden CL, Carroll MD, Flegal KM. High body mass index for age among US children and adolescents, 2003-2006. JAMA. 2008;299(20):2401-5.
3. Haslam DW, James WP. Obesity. Lancet. 2005; 366(9492): 1197-209.
4. Kopelman PG. Obesity as a medical problem. Nature. 2000;404(6778):635-43.
5. Bouchard C. Current understanding of the etiology of obesity: genetic and nongenetic factors. Am J Clin Nutr. 1991;53(6):1561S-5S.
6. Goran MI, Weinsier RL. Role of environmental vs. metabolic factors in the etiology of obesity: time to focus on the environment. Obes Res. 2000;8(5):407-9.
7. Weinsier RL, Hunter GR, Heini AF, et al. The etiology of obesity: relative contribution of metabolic factors, diet, and physical activity. Am J Med. 1998;105(2): 145-50.
8. Guidelines for the approval and use of drugs to treat obesity. A position paper of The North American Association for the Study of Obesity. Obes Res 1995;3(5):473-8.
9. Atkinson RL. Use of drugs in the treatment of obesity. Annu Rev Nutr. 1997;17:383-403.
10. Bray GA, DeLany J. Opinions of obesity experts on the causes and treatment of obesity-a new survey. Obes Res. 1995;3 Suppl 4:419S-23S.
11. Bray GA, Ryan DH. Drug treatment of the overweight patient. Gastroenterology. 2007;132(6): 2239-52.
12. Finer N. Present and future pharmacological approaches. Br Med Bull. 1997;53(2):409-32.
13. Bray GA. Evaluation of drugs for treating obesity. Obes Res. 1995;3 Suppl 4:425S-34S.
14. Guy-Grand B. Pharmacological approaches to intervention. Int J Obes Relat Metab Disord. 1997;21 Suppl 1:S22-4.
15. Henry JP. A case of myxoedema cured by thyroid extract. Br Med J. 1893;1(1684):737-8.
16. Rivlin RS. Therapy of obesity with hormones. N Engl J Med. 1975;292(1):26-9.
17. Bhasin S, Wallace W, Lawrence JB, Lesch M. Sudden death associated with thyroid hormone abuse. Am J Med. 1981;71(5):887-90.
18. Mittleman RE, Goldberg RB, Nadji M. Severe thyroid atrophy due to prolonged ingestion of thyroid hormone for treatment of obesity. South Med J. 1984;77(2):268-70.
19. Boardman WW. Rapidly developing cataracts after dinitrophenol. Cal West Med. 1935;43(2):118-9.
20. Cutting WC, Rytand DA, Tainter ML. Relationship between blood cholesterol and increased metabolism from dinitrophenol and thyroid. J Clin Invest. 1934; 13(4):547-52.
21. Koch RA, Lee RC, Tainter ML. Dinitrophenol on liver function. Cal West Med. 1935;43(5):337-9.
22. Lesses MF, Myerson A. Human autonomic pharmacology. XVI. Benzedrine sulfate as an aid in the treatment of obesity. 1938. Obes Res. 1994;2(3): 286-92.
23. Mayer J. Genetic, traumatic and environmental factors in the etiology of obesity. Physiol Rev. 1953;33(4):472-508.
24. Jelliffe RW, Hill D, Tatter D, Lewis Jr E. Death from weight-control pills. A case report with objective postmortem confirmation. JAMA. 1969;208(10): 1843-7.
25. Kaplan NM, Jose A. Thyroid as an adjuvant to amphetamine therapy of obesity. A controlled double-blind study. Am J Med Sci. 1970;260(2):105-11.
26. Kattus Jr AA, Biscoe BW, Dashe AM, Davis JH. Spurious heart disease induced by digitalis-containing reducing pills. Arch Intern Med. 1968;122(4):298-304.
27. Smith HJ, Roche AH, Jausch MF, Herdson PB. Cardiomyopathy associated with amphetamine administration. Am Heart J. 1976;91(6):792-7.
28. Follath F, Burkart F, Schweizer W. Drug-induced pulmonary hypertension? Br Med J. 1971;1(5743): 265-6.
29. Soong YS. The treatment of exogenous obesity employing auricular acupuncture. Am J Chin Med (Gard City N Y). 1975;3(3):285-7.
30. Van Itallie TB, Yang MU. Cardiac dysfunction in obese dieters: a potentially lethal complication of rapid, massive weight loss. Am J Clin Nutr. 1984; 39(5):695-702.
31. Silverstone T. Appetite suppressants. A review. Drugs. 1992;43(6):820-36.
32. Weintraub M. Long-term weight control study: conclusions. Clin Pharmacol Ther. 1992;51(5):642-6.
33. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine- phentermine. N Engl J Med. 1997;337(9):581-8.
34. Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med. 2000;343(25):1826-32.
35. Astrup A, Breum L, Toubro S. Pharmacological and clinical studies of ephedrine and other thermogenic agonists. Obes Res. 1995;3 Suppl 4:537S-40S.
36. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med. 2000;343(25):1833-8.
37. Daly PA, Krieger DR, Dulloo AG, et al. Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity. Int J Obes Relat Metab Disord. 1993;17 Suppl 1:S73-8.
38. Hallas J, Bjerrum L, Stovring H, Andersen M. Use of a prescribed ephedrine/caffeine combination and the risk of serious cardiovascular events: a registry- based case-crossover study. Am J Epidemiol. 2008;168(8):966-73.
39. Hadvary P, Lengsfeld H, Wolfer H. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetra- hydrolipstatin. Biochem J. 1988;256(2):357-61.
40. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord. 1997;21 Suppl 3:S12-23.
41. Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther. 1994; 56(1):82-5.
42. Drent ML, van der Veen EA. Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes Relat Metab Disord. 1993;17(4):241-4.
43. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999;281(3):235-42.
44. Drent ML, Larsson I, William-Olsson T, et al. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes Relat Metab Disord. 1995;19(4):221-6.
45. Cavaliere H, Floriano I, Medeiros-Neto G. Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid). Int J Obes Relat Metab Disord. 2001;25 (7): 1095-9.
46. Halpern A, Mancini MC, Suplicy H, et al. Latin- American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes Obes Metab. 2003;5(3):180-8.
47. Zhi J, Melia AT, Eggers H, et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol. 1995; 35 (11): 1103-8.
48. McDuffie JR, Calis KA, Booth SL, et al. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy. 2002;22(7):814-22.
49. Colman E, Fossler M. Reduction in blood cyclosporine concentrations by orlistat. N Engl J Med. 2000;342(15):1141-2.
50. Filippatos TD, Derdemezis CS, Gazi IF, et al. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf. 2008;31(1): 53-65.
51. Mac Walter RS, Fraser HW, Armstrong KM. Orlistat enhances warfarin effect. Ann Pharmacother. 2003; 37(4):510-2.
52. Ahmed MH. Orlistat and calcium oxalate crystallu- ria: an association that needs consideration. Ren Fail. 2010;32(8):1019-21.
53. Schwartz SM, Bansal VP, Hale C, et al. Compliance, behavior change, and weight loss with orlistat in an over-the-counter setting. Obesity (Silver Spring). 2008;16(3):623-9.
54. King DJ, Devaney N. Clinical pharmacology of sibutramine hydrochloride (BTS 54524), a new antidepressant, in healthy volunteers. Br J Clin Pharmacol. 1988;26(5):607-11.
55. Stock MJ. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes Relat Metab Disord. 1997;21 Suppl 1:S25-9.
56. Bach DS, Rissanen AM, Mendel CM, et al. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes Res. 1999;7(4):363-9.
57. Bae SK, Cao S, Seo KA, et al. Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl) cyclobutyl]-3-methylbutyl}-N, N-dimethylamine) metabolites in human liver microsomes. Drug Metab Dispos. 2008;36(8):1679-88.
58. Bray GA, Ryan DH, Gordon D, et al. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res. 1996;4(3):263-70.
59. Apfelbaum M, Vague P, Ziegler O, et al. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med. 1999;106(2): 179-84.
60. Dujovne CA, Zavoral JH, Rowe E, Mendel CM. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebocontrolled study in 322 overweight and obese patients with dyslipidemia. Am Heart J. 2001;142(3): 489-97.
61. Hazenberg BP. Randomized, double-blind, placebocontrolled, multicenter study of sibutramine in obese hypertensive patients. Cardiology. 2000;94(3): 152-8.
62. McMahon FG, Fujioka K, Singh BN, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med. 2000;160(14):2185-91.
63. Smith IG, Goulder MA. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract. 2001; 50(6):505-12.
64. Florentin M, Liberopoulos EN, Elisaf MS. Sibutramine-associated adverse effects: a practical guide for its safe use. Obes Rev. 2008;9(4):378-87.
65. Ioannides-Demos LL, Proietto J, McNeil JJ. Pharmacotherapy for obesity. Drugs. 2005;65(10): 1391-418.
66. Anderson JW, Greenway FL, Fujioka K, et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes Res. 2002;10(7):633-41.
67. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142(7):532-46.
68. Fuller RW, Wong DT. Serotonin uptake and serotonin uptake inhibition. Ann N Y Acad Sci. 1990;600:68-78. discussion 9-80.
69. Koe BK, Weissman A, Welch WM, Browne RG. Sertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin. J Pharmacol Exp Ther. 1983;226(3):686-700.
70. Goldstein DJ, Rampey Jr AH, Roback PJ, et al. Efficacy and safety of long-term fluoxetine treatment of obesity-maximizing success. Obes Res. 1995;3 Suppl 4:481S-90S.
71. Wise SD. Clinical studies with fl uoxetine in obesity. Am J Clin Nutr. 1992;55(1 Suppl):181S-4S.
72. Wadden TA, Bartlett SJ, Foster GD, et al. Sertraline and relapse prevention training following treatment by very-low-calorie diet: a controlled clinical trial. Obes Res. 1995;3(6):549-57.
73. Darga LL, Carroll-Michals L, Botsford SJ, Lucas CP. Fluoxetine’s effect on weight loss in obese subjects. Am J Clin Nutr. 1991;54(2):321-5.
74. Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res. 2003;11(6):722-33.
75. Wilensky AJ, Friel PN, Ojemann LM, et al. Zonisamide in epilepsy: a pilot study. Epilepsia. 1985;26(3):212-20.
76. Gadde KM, Franciscy DM, Wagner 2nd HR, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA. 2003;289(14): 1820-5.
77. Gadde KM, Yonish GM, Foust MS, Wagner HR. Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. J Clin Psychiatry. 2007;68(8): 1226-9.
78. Munro JF, MacCuish AC, Marshall A, et al. Weight- reducing effect of diguanides in obese non-diabetic women. Br Med J. 1969;2(5648):13-5.
79. Fendri S, Debussche X, Puy H, et al. Metformin effects on peripheral sensitivity to insulin in non diabetic obese subjects. Diabete Metab. 1993;19(2): 245-9.
80. Baysal B, Batukan M, Batukan C. Biochemical and body weight changes with metformin in polycystic ovary syndrome. Clin Exp Obstet Gynecol. 2001; 28(4):212-4.
81. Atabek ME, Pirgon O. Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial. J Pediatr Endocrinol Metab. 2008;21(4): 339-48.
82. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics. 2001;107(4): E55.
83. Love-Osborne K, Sheeder J, Zeitler P. Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J Pediatr. 2008;152(6):817-22.
84. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res. 1998;6(1):47-53.
85. Blankson H, Stakkestad JA, Fagertun H, et al. Conjugated linoleic acid reduces body fat mass in overweight and obese humans. J Nutr. 2000;130(12): 2943-8.
86. Gaullier JM, Halse J, Hoye K, et al. Conjugated lino- leic acid supplementation for 1 y reduces body fat mass in healthy overweight humans. Am J Clin Nutr. 2004;79(6):1118-25.
87. Larsen TM, Toubro S, Gudmundsen O, Astrup A. Conjugated linoleic acid supplementation for 1 y does not prevent weight or body fat regain. Am J Clin Nutr. 2006;83(3):606-12.
88. Gaullier JM, Halse J, Hoye K, et al. Supplementation with conjugated linoleic acid for 24 months is well tolerated by and reduces body fat mass in healthy, overweight humans. J Nutr. 2005;135(4):778-84.
89. Kafetzopoulos D, Martinou A, Bouriotis V. Bioconversion of chitin to chitosan: purification and characterization of chitin deacetylase from Mucor rouxii. Proc Natl Acad Sci USA. 1993;90(7): 2564-8.
90. Pittler MH, Abbot NC, Harkness EF, Ernst E. Randomized, double-blind trial of chitosan for body weight reduction. Eur J Clin Nutr. 1999;53(5): 379-81.
91. Mhurchu CN, Poppitt SD, McGill AT, et al. The effect of the dietary supplement, Chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults. Int J Obes Relat Metab Disord. 2004;28(9):1149-56.
92. Zahorska-Markiewicz B, Krotkiewski M, Olszanecka-Glinianowicz M, Zurakowski A. Effect of chitosan in complex management of obesity. Pol Merkur Lekarski. 2002;13(74):129-32.
93. Kaats GR, Michalek JE, Preuss HG. Evaluating efficacy of a chitosan product using a double-blinded, placebo-controlled protocol. J Am Coll Nutr. 2006;25(5):389-94.
94. Pittler MH, Schmidt K, Ernst E. Adverse events of herbal food supplements for body weight reduction: systematic review. Obes Rev. 2005;6(2):93-111.
95. Andersen T, Fogh J. Weight loss and delayed gastric emptying following a South American herbal preparation in overweight patients. J Hum Nutr Diet. 2001;14(3):243-50.
96. Pittler MH, Ernst E. Guar gum for body weight reduction: meta-analysis of randomized trials. Am J Med. 2001;110(9):724-30.
97. Zhang J, Kang MJ, Kim MJ, et al. Pancreatic lipase inhibitory activity of taraxacum officinale in vitro and in vivo. Nutr Res Pract. 2008;2(4):200-3.
98. Heymsfield SB, Allison DB, Vasselli JR, et al. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial. JAMA. 1998;280(18):1596-600.
99. Preuss HG, Bagchi D, Bagchi M, et al. Effects of a natural extract of (-)-hydroxycitric acid (HCA-SX) and a combination of HCA-SX plus niacin-bound chromium and Gymnema sylvestre extract on weight loss. Diabetes Obes Metab. 2004;6(3):171-80.
100. Vasques CA, Rossetto S, Halmenschlager G, et al. Evaluation of the pharmacotherapeutic efficacy of Garcinia cambogia plus Amorphophallus konjac for the treatment of obesity. Phytother Res. 2008; 22(9):1135-40.
101. Keithley J, Swanson B. Glucomannan and obesity: a critical review. Altern Ther Health Med. 2005; 11(6):30-4.
102. Anderson RA. Effects of chromium on body composition and weight loss. Nutr Rev. 1998;56(9): 266-70.
103. Yazaki Y, Faridi Z, Ma Y, et al. A pilot study of chromium picolinate for weight loss. J Altern Complement Med. 2010;16(3):291-9.
104. Kao YH, Chang HH, Lee MJ, Chen CL. Tea, obesity, and diabetes. Mol Nutr Food Res. 2006;50(2): 188-210.
105. Boschmann M, Thielecke F. The effects of epigallo- catechin-3-gallate on thermogenesis and fat oxidation in obese men: a pilot study. J Am Coll Nutr. 2007;26(4):389S-95S.
106. Takabayashi F, Tahara S, Kaneko T, Harada N. Effect of green tea catechins on oxidative DNA damage of hamster pancreas and liver induced by N-Nitrosobis (2-oxopropyl)amine and/or oxidized soybean oil. Biofactors. 2004;21(1-4):335-7.
107. Kalman D, Colker CM, Wilets I, et al. The effects of pyruvate supplementation on body composition in overweight individuals. Nutrition. 1999;15(5): 337-40.
108. Stanko RT, Tietze DL, Arch JE. Body composition, energy utilization, and nitrogen metabolism with a 4.25-MJ/d low-energy diet supplemented with pyruvate. Am J Clin Nutr. 1992;56(4):630-5.
109. Kopelman P, Bryson A, Hickling R, et al. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond). 2007;31(3):494-9.
110. Bryson A, de la Motte S, Dunk C. Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers. Br J Clin Pharmacol. 2009;67(3):309-15.
111. Kamisuki S, Mao Q, Abu-Elheiga L, et al. A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. Chem Biol. 2009;16(8): 882-92.
112. Arch JR, Ainsworth AT, Cawthorne MA, et al. Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature. 1984; 309(5964): 163-5.
113. Weyer C, Tataranni PA, Snitker S, et al. Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans. Diabetes. 1998;47(10):1555-61.
114. Redman LM, de Jonge L, Fang X, et al. Lack of an effect of a novel beta3-adrenoceptor agonist, TAK- 677, on energy metabolism in obese individuals: a double-blind, placebo-controlled randomized study. J Clin Endocrinol Metab. 2007;92(2):527-31.
115. Astrup A, Madsbad S, Breum L, et al. Effect of tes- ofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9653): 1906-13.
116. Green way FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring). 2009; 17(1):30-9.
117. Green way FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595-605.
118. Roth BL, Willins DL, Kristiansen K, Kroeze WK. 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. Pharmacol Ther. 1998;79(3):231-57.
119. Thomsen WJ, Grottick AJ, Menzaghi F, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther. 2008;325(2):577-87.
120. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010; 363(3):245-56.
121. Carai MA, Colombo G, Gessa GL. Rimonabant: the first therapeutically relevant cannabinoid antagonist. Life Sci. 2005;77(19):2339-50.
122. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007;369(9555):71-7.
123. Van Gaal L, Pi-Sunyer X, Despres JP, et al. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care. 2008;31 Suppl 2:S229-40.
124. Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimona- bant: a meta-analysis of randomised trials. Lancet. 2007;370(9600): 1706-13.
125. Christopoulou FD, Kiortsis DN. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity. J Clin Pharm Ther. 2011;36(1): 10-8.
126. Addy C, Wright H, Van Laere K, et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab. 2008;7(1): 68-78.
127. Proietto J, Rissanen A, Harp JB, et al. A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study. Int J Obes (Lond). 2010;34(8): 1243-54.
128. Aronne LJ, Tonstad S, Moreno M, et al. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. Int J Obes (Lond). 2010;34(5):919-35.
129. Koch L. Obesity: taranabant no longer developed as an antiobesity agent. Nat Rev Endocrinol. 2010; 6(6):300.
130. Maffei M, Halaas J, Ravussin E, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med. 1995;1(11):1155-61.
131. Ahima RS, Saper CB, Flier JS, Elmquist JK. Leptin regulation of neuroendocrine systems. Front Neuroendocrinol. 2000;21(3):263-307.
132. Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neurosci. 2005;8(5): 571-8.
133. Cowley MA, Smart JL, Rubinstein M, et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature. 2001;411 (6836):480-4.
134. Schwartz MW, Woods SC, Porte Jr D, et al. Central nervous system control of food intake. Nature. 2000;404(6778):661-71.
135. Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA. 1999;282(16):1568-75.
136. Van Heek M, Compton DS, France CF, et al. Diet- induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest. 1997;99(3): 385-90.
137. Ozcan L, Ergin AS, Lu A, et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab. 2009;9(1):35-51.
138. Lo KM, Zhang J, Sun Y, et al. Engineering a pharmacologically superior form of leptin for the treatment of obesity. Protein Eng Des Sel. 2005; 18 (1): 1-10.
139. Wannamethee SG, Tchernova J, Whincup P, et al. Plasma leptin: associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease. Atherosclerosis. 2007; 191(2): 418-26.
140. Uwaifo GI, Ratner RE. Novel pharmacologic agents for type 2 diabetes. Endocrinol Metab Clin North Am. 2005;34(1):155-97.
141. Hoogwerf BJ, Doshi KB, Diab D. Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk. Vasc Health Risk Manag. 2008;4(2):355-62.
142. Aronne L, Fujioka K, Aroda V, et al. Progressive reduction in body weight after treatment with the amy- lin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab. 2007;92(8):2977-83.
143. Smith SR, Aronne LJ, Burns CM, et al. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care. 2008;31(9):1816-23.
144. Dunican KC, Adams NM, Desilets AR. The role of pramlintide for weight loss. Ann Pharmacother. 2010;44(3):538-45.
145. Mack CM, Soares CJ, Wilson JK, et al. Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight. Int J Obes (Lond). 2010;34(2):385-95.
146. Roth JD, Roland BL, Cole RL, et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci USA. 2008;105(20): 7257-62.
147. Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring). 2009; 17(9): 1736-43.
148. Naslund E, King N, Mansten S, et al. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr. 2004;91 (3):439-46.
149. Verdich C, Flint A, Gutzwiller JP, et al. Ameta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab. 2001;86(9):4382-9.
150. Poon T, Nelson P, Shen L, et al. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther. 2005;7(3):467-77.
151. Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glyce- mic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30(6):1608-10.
152. Rosenstock J, Klaff LJ, Schwartz S, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care. 2010;33(6):1173-5.
153. Madsbad S, Kielgast U, Asmar M, et al. An overview of once-weekly GLP-1 receptor agonists - available efficacy and safety data and perspectives for the future. Diabetes Obes Metab. 2011; 13: 394-407.
154. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84-90.
155. Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701): 1606-16.
156. Day JW, Ottaway N, Patterson JT, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. 2009;5(10):749-57.
157. Stanley S, Wynne K, Bloom S. Gastrointestinal satiety signals III. Glucagon-like peptide 1, oxyntomod- ulin, peptide YY, and pancreatic polypeptide. Am J Physiol Gastrointest Liver Physiol. 2004;286(5): G693-7.
158. Dakin CL, Small CJ, Batterham RL, et al. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology. 2004;145(6):2687-95.
159. Dakin CL, Gunn I, Small CJ, et al. Oxyntomodulin inhibits food intake in the rat. Endocrinology. 2001;142(10):4244-50.
160. Cohen MA, Ellis SM, Le Roux CW, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab. 2003;88(10):4696-701.
161. Wynne K, Park AJ, Small CJ, et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes. 2005;54(8):2390-5.
162. Wynne K, Park AJ, Small CJ, et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond). 2006;30(12): 1729-36.
163. Polak JM, Bloom SR, Rayford PL, et al. Identification of cholecystokinin-secreting cells. Lancet. 1975; 2(7943):1016-8.
164. Dufresne M, Seva C, Fourmy D. Cholecystokinin and gastrin receptors. Physiol Rev. 2006;86(3): 805-47.
165. Gibbs J, Young RC, Smith GP. Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol. 1973;84(3):488-95.
166. Lieverse RJ, Jansen JB, Masclee AA, Lamers CB. Satiety effects of a physiological dose of cholecystokinin in humans. Gut. 1995;36(2):176-9.
167. Pi-Sunyer X, Kissileff HR, Thornton J, Smith GP. C-terminal octapeptide of cholecystokinin decreases food intake in obese men. Physiol Behav. 1982; 29(4):627-30.
168. Crawley JN, Beinfeld MC. Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature. 1983;302(5910):703-6.
169. Matson CA, Reid DF, Ritter RC. Daily CCK injection enhances reduction of body weight by chronic intracerebroventricular leptin infusion. Am J Physiol Regul Integr Comp Physiol. 2002;282(5): R1368-73.
170. Wang L, Barachina MD, Martinez V, et al. Synergistic interaction between CCK and leptin to regulate food intake. Regul Pept. 2000;92(1-3):79-85.
171. Zac-Varghese S, Tan T, Bloom SR. Hormonal interactions between gut and brain. Discov Med. 2010;10(55):543-52.
172. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-60.
173. Yang J, Brown MS, Liang G, et al. Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell. 2008;132(3):387-96.
174. Kamegai J, Tamura H, Shimizu T, et al. Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-related protein mRNA levels and body weight in rats. Diabetes. 2001;50(11): 2438-43.
175. Tamura H, Kamegai J, Shimizu T, et al. Ghrelin stimulates GH but not food intake in arcuate nucleus ablated rats. Endocrinology. 2002;143(9):3268-75.
176. Cummings DE, Purnell JQ, Frayo RS, et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001;50(8): 1714-9.
177. Tschop M, Wawarta R, Riepl RL, et al. Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest. 2001;24(6):RC19-21.
178. Cummings DE, Frayo RS, Marmonier C, et al. Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time- and food- related cues. Am J Physiol Endocrinol Metab. 2004;287(2):E297-304.
179. Salbe AD, Tschop MH, DelParigi A, et al. Negative relationship between fasting plasma ghrelin concentrations and ad libitum food intake. J Clin Endocrinol Metab. 2004;89(6):2951-6.
180. Tschop M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001;50(4):707-9.
181. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000;407(6806): 908-13.
182. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86(12):5992.
183. Strassburg S, Anker SD, Castaneda TR, et al. Longterm effects of ghrelin and ghrelin receptor agonists on energy balance in rats. Am J Physiol Endocrinol Metab. 2008;295(1):E78-84.
184. Halem HA, Taylor JE, Dong JZ, et al. A novel growth hormone secretagogue-1a receptor antagonist that blocks ghrelin-induced growth hormone secretion but induces increased body weight gain. Neuroendocrinology. 2005;81(5):339-49.
185. Helmling S, Maasch C, Eulberg D, et al. Inhibition of ghrelin action in vitro and in vivo by an RNA- Spiegelmer. Proc Natl Acad Sci USA. 2004; 101(36):13174-9.
186. Kobelt P, Helmling S, Stengel A, et al. Anti-ghrelin Spiegelmer NOX-B11 inhibits neurostimulatory and orexigenic effects of peripheral ghrelin in rats. Gut. 2006;55(6):788-92.
187. Shearman LP, Wang SP, Helmling S, et al. Ghrelin neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice. Endocrinology. 2006;147(3):1517-26.
188. Diniz Mde F, Azeredo Passos VM, Diniz MT. Bariatric surgery and the gut-brain communication- the state of the art three years later. Nutrition. 2010;26(10):925-31.
189. Tritos NA, Maratos-Flier E. Two important systems in energy homeostasis: melanocortins and melaninconcentrating hormone. Neuropeptides. 1999;33(5): 339-49.
190. Shimada M, Tritos NA, Lowell BB, et al. Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature. 1998;396(6712):670-4.
191. Ito M, Gomori A, Ishihara A, et al. Characterization of MCH-mediated obesity in mice. Am J Physiol Endocrinol Metab. 2003;284(5):E940-5.
192. Ludwig DS, Tritos NA, Mastaitis JW, et al. Melaninconcentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. J Clin Invest. 2001;107(3):379-86.
193. An S, Cutler G, Zhao JJ, et al. Identification and characterization of a melanin-concentrating hormone receptor. Proc Natl Acad Sci USA. 2001; 98(13):7576-81.
194. Marsh DJ, Weingarth DT, Novi DE, et al. Melaninconcentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proc Natl Acad Sci USA. 2002;99(5): 3240-5.
195. Kowalski TJ, McBriar MD. Therapeutic potential of melanin-concentrating hormone-1 receptor antagonists for the treatment of obesity. Expert Opin Investig Drugs. 2004;13(9):1113-22.
196. Borowsky B, Durkin MM, Ogozalek K, et al. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat Med. 2002;8(8):825-30.
197. Ito M, Ishihara A, Gomori A, et al. Mechanism of the anti-obesity effects induced by a novel melanin-concentrating hormone 1-receptor antagonist in mice. Br J Pharmacol. 2010;159(2):374-83.
198. Kowalski TJ, Spar BD, Weig B, et al. Effects of a selective melanin-concentrating hormone 1 receptor antagonist on food intake and energy homeostasis in diet-induced obese mice. Eur J Pharmacol. 2006;535(1-3): 182-91.
199. Audinot V, Zuana OD, Fabry N, et al. S38151 [p-guanidinobenzoyl-[Des-Gly(10)]-MCH(7-17)] is a potent and selective antagonist at the MCH(1) receptor and has anti-feeding properties in vivo. Peptides. 2009;30(11):1997-2007.
200. Mountjoy KG, Mortrud MT, Low MJ, et al. Localization of the melanocortin-4 receptor (MC4- R) in neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol. 1994;8(10):1298-308.
201. Roselli-Rehfuss L, Mountjoy KG, Robbins LS, et al. Identification of a receptor for gamma melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. Proc Natl Acad Sci USA. 1993;90(19):8856-60.
202. Murphy B, Nunes CN, Ronan JJ, et al. Melanocortin mediated inhibition of feeding behavior in rats. Neuropeptides. 1998;32(6):491-7.
203. Trivedi P, Jiang M, Tamvakopoulos CC, et al. Exploring the site of anorectic action of peripherally administered synthetic melanocortin peptide MT-II in rats. Brain Res. 2003;977(2):221-30.
204. Kuo JJ, Silva AA, Hall JE. Hypothalamic melanocortin receptors and chronic regulation of arterial pressure and renal function. Hypertension. 2003; 41(3 Pt 2):768-74.
205. Krishna R, Gumbiner B, Stevens C, et al. Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy. Clin Pharmacol Ther. 2009;86(6):659-66.
206. Stanley BG, Magdalin W, Seirafi A, et al. The perifornical area: the major focus of (a) patchily distributed hypothalamic neuropeptide Y-sensitive feeding system(s). Brain Res. 1993;604(1-2):304-17.
207. Stanley BG, Kyrkouli SE, Lampert S, Leibowitz SF. Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides. 1986;7(6): 1189-92.
208. Gerald C, Walker MW, Criscione L, et al. A receptor subtype involved in neuropeptide-Y-induced food intake. Nature. 1996;382(6587):168-71.
209. Criscione L, Rigollier P, Batzl-Hartmann C, et al. Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor. J Clin Invest. 1998;102(12): 2136-45.
210. Erondu N, Gantz I, Musser B, et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab. 2006;4(4):275-82.
211. Widdowson PS, Henderson L, Pickavance L, et al. Hypothalamic NPY status during positive energy balance and the effects of the NPY antagonist, BW 1229U91, on the consumption of highly palatable energy-rich diet. Peptides. 1999;20(3): 367-72.